Biodegradable Nanogels a Promising, Enhanced Drug Delivery Method in Lupus

VBCR - June 2013, Volume 2, No 3 - Value Propositions

A drug delivery system designed by researchers at Yale University shows promise for the treatment of lupus and other chronic autoimmune diseases.

The team used biodegradable nanoparticles to deliver low doses of drugs in an early-stage study. The use of these drug-laden nanoparticles, called nanogels, increased the median survival time of mice with lupus by 3 months. The median survival time was increased by 2 months in mice that already had severe kidney damage as a result of lupus.

“Three months of a mouse’s life is roughly equivalent to more than 8 years of a human life, so this is dramatic,” said Tarek Fahmy, Associate Professor of Biomedical Engineering at Yale University. “The potential for human benefit is clear and promising.”

Compared with conventional therapies for lupus, the nanogels improve the drug delivery to the cells and enhance drug retention in the body, allowing for the use of significantly lower drug doses. In addition, drug delivery via nanogels works without depleting white blood cells, which reduces the patient’s risk for infection.

Nanogels are made of organic materials and can circulate for longer periods of time in the body than conventional drugs because of their size and their ability to pass biological barriers. They can also be programmed to target specific cells, such as T-cells and antigen-presenting cells, thereby deactivating them and suppressing their response, which would minimize the symptoms of lupus.

The nanogels are made of materials approved by the US Food and Drug Administration and could therefore shorten the process involved in preparing them for human use. Yale News; March 1, 2013

Related Items
Value Propositions - April 2018
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Value Propositions
Value Propositions - October 2017
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Value Propositions
Value Propositions - August 2017
VBCR - August 2017, Vol 6, No 3 published on August 23, 2017 in Value Propositions
Value Propositions - June 2017
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Value Propositions
Value Propositions - April 2017
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Value Propositions
Value Propositions - December 2016
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Value Propositions
Value Propositions - October 2016
VBCR - October 2016, Vol 5, No 5 published on November 2, 2016 in Value Propositions
Value Propositions - August 2016
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Value Propositions
Value Propositions - June 2016
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Value Propositions
Value Propositions - April 2016
VBCR - April 2016, Vol 5, No 2 published on May 14, 2016 in Value Propositions
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology